SOHO 2026 Sessions Reveal Key Updates Across Leukemia Populations (Cancer Network) - Sep 14, 2026 - "Combining olverembatinib (HQP1351), a novel third-generation BCR-ABL TKI, with blinatumomab (Blincyto) produced favorable responses among patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome (Ph)–positive B-cell precursor ALL in a phase 1b study (NCT04260022)....Among 13 enrolled patients, a complete response (CR) occurred in 90.9% (n = 10/11) of the population, and 66.7% (n = 8/12) experienced a molecular response (MR) 4.0. Minimal residual disease negativity (MRD) at 10–4 sensitivity was reported in 80% (n = 8/10) of patients. Regarding safety, 46% (n = 6/13) of patients had grade 3/4 treatment-related AEs (TRAEs) associated with olverembatinib, and 39% (n = 5/13) had grade 3/4 TRAEs associated with blinatumomab."
P1 data • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia
|